MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

NCT05494736 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus

Interventions

DRUG: MK-8527

Sponsor

Merck Sharp & Dohme LLC